Increased methylation upstream of the MEG3 promotor is observed in acute myeloid leukemia patients with better overall survival

Table 5 The median (range) values of methylation of studied CpG sites and chosen gene expression

Analysis	AML patient MNCs Median (range) [number of patient]	Control MNCs Median (range) [number of sample]
Methylation (%)
CG6	88.28 (5.00–99.53) [44]	60.89 (48.75–70.89) [9]
CG7	74.45 (32.65–97.69) [42]	60.21 (24.98–72.70) [9]
CG8	91.91 (30.43–99.65) [44]	65.65 (60.11–82.36) [9]
CG9	55.34 (7.86–91.73) [42]	46.53 (39.23–60.13) [8]
ZAC	49.24 (18.96–71.97) [42]	62.91 (46.50–78.97) [8]
IGF2-H19	70.20 (40.97–99.56) [45]	78.12 (68.64–86.20) [9]
PEG3	67.18 (15.95–98.10) [42]	67.41 (41.82–79.71) [9]
PEG1	56.29 (23.08–95.13) [45]	66.74 (57.85–68.91) [9]
Expression (∆Ct)
DLK1 (× 10⁻⁷)	50.98 (0.88–161,542.28) [29]
MEG3 (× 10^− 6)	34.189 (1.36–19,339.85) [29]
DLK1/MEG3 (× 10^− 2)	10.31 (0.20–1121.10) [29]